Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 2
2010 4
2011 5
2012 13
2013 15
2014 18
2015 20
2016 16
2017 22
2018 16
2019 27
2020 25
2021 20
2022 26
2023 20
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Results by year

Filters applied: . Clear all
Page 1
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol V, Dréno B, Fargnoli MC, Forsea AM, Grob JJ, Hoeller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Lytvynenko B, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). Garbe C, et al. Eur J Cancer. 2022 Jul;170:256-284. doi: 10.1016/j.ejca.2022.04.018. Epub 2022 May 24. Eur J Cancer. 2022. PMID: 35623961 Free article. Review.
In stage IV melanoma with a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harboring a BRAF-V600 E/K mutation, this ther …
In stage IV melanoma with a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an al …
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era.
Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH, Hershkovitz-Rokah O, Girschikofsky M, Jacobsen ED, Toyama K, Goodman AM, Hendrie P, Cao XX, Estrada-Veras JI, Shpilberg O, Abdo A, Kurokawa M, Dagna L, McClain KL, Mazor RD, Picarsic J, Janku F, Go RS, Haroche J, Diamond EL. Goyal G, et al. Blood. 2020 May 28;135(22):1929-1945. doi: 10.1182/blood.2019003507. Blood. 2020. PMID: 32187362 Free article. Review.
With the recent molecular discoveries and the approval of the first targeted therapy (vemurafenib) for BRAF-V600-mutant ECD, there is a need for updated clinical practice guidelines to optimize the diagnosis and treatment of this disease. ...
With the recent molecular discoveries and the approval of the first targeted therapy (vemurafenib) for BRAF-V600-mutant …
Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.
Troussard X, Maître E, Cornet E. Troussard X, et al. Am J Hematol. 2022 Feb 1;97(2):226-236. doi: 10.1002/ajh.26390. Epub 2021 Nov 8. Am J Hematol. 2022. PMID: 34710243 Free article.
TREATMENT: Patients should be treated only if HCL is symptomatic. Chemotherapy with risk adapted therapy purine analogs (PNAs) are indicated in first-line HCL patients. The use of chemo-immunotherapy combining PNAs and rituximab (R) represents an increasingly used thera …
TREATMENT: Patients should be treated only if HCL is symptomatic. Chemotherapy with risk adapted therapy purine analogs (PNAs) are in …
Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment.
Maitre E, Cornet E, Troussard X. Maitre E, et al. Am J Hematol. 2019 Dec;94(12):1413-1422. doi: 10.1002/ajh.25653. Epub 2019 Oct 31. Am J Hematol. 2019. PMID: 31591741 Free article. Review.
The VH4-34 positive HCL cases are associated with poor prognosis. TREATMENT: Risk adapted therapy with purine nucleoside analogs (PNA) are indicated in symptomatic first line HCL patients. ...Management of progressive or refractory disease is based on the use of BRAF …
The VH4-34 positive HCL cases are associated with poor prognosis. TREATMENT: Risk adapted therapy with purine nucleoside analogs (PNA …
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
Grothey A, Fakih M, Tabernero J. Grothey A, et al. Ann Oncol. 2021 Aug;32(8):959-967. doi: 10.1016/j.annonc.2021.03.206. Epub 2021 Apr 7. Ann Oncol. 2021. PMID: 33836264 Free article. Review.
Combination strategies involving mitogen-activated protein kinase (MAPK) pathway blockade have shown promising results for the treatment of patients with BRAF V600E-mutated mCRC. The Binimetinib, Encorafenib, And Cetuximab cOmbiNed to treat BRAF-mutant …
Combination strategies involving mitogen-activated protein kinase (MAPK) pathway blockade have shown promising results for the treatm …
European expert panel consensus on the clinical management of BRAF(V600E)-mutant metastatic colorectal cancer.
Martinelli E, Arnold D, Cervantes A, Stintzing S, Van Cutsem E, Tabernero J, Taieb J, Wasan H, Ciardiello F. Martinelli E, et al. Cancer Treat Rev. 2023 Apr;115:102541. doi: 10.1016/j.ctrv.2023.102541. Epub 2023 Mar 11. Cancer Treat Rev. 2023. PMID: 36931147 Free article. Review.
Here we review the current knowledge on BRAF(V600E)-mutant mCRC and provide a series of consensus statements on its clinical management. The treatment landscape for BRAF(V600E)-mutant mCRC has changed greatly due to the emergence of molecular targeted …
Here we review the current knowledge on BRAF(V600E)-mutant mCRC and provide a series of consensus statements on its clinical m …
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers.
Ros J, Rodríguez-Castells M, Saoudi N, Baraibar I, Salva F, Tabernero J, Élez E. Ros J, et al. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(8):797-806. doi: 10.1080/14737140.2023.2236794. Epub 2023 Jul 23. Expert Rev Anticancer Ther. 2023. PMID: 37482749 Review.
Unlike melanoma, the development of successful BRAF blockade in colorectal cancer has been complex. The phase III BEACON trial made significant progress in the development of BRAF inhibitors by establishing encorafenib-cetuximab as the new standard of care fo …
Unlike melanoma, the development of successful BRAF blockade in colorectal cancer has been complex. The phase III BEACON trial made s …
Management of V600E and V600K BRAF-Mutant Melanoma.
Haugh AM, Johnson DB. Haugh AM, et al. Curr Treat Options Oncol. 2019 Nov 18;20(11):81. doi: 10.1007/s11864-019-0680-z. Curr Treat Options Oncol. 2019. PMID: 31741065 Free PMC article. Review.
Decisions regarding first line therapy should include consideration of patient preference as well as the presence of symptomatic metastatic disease and degree of comorbidity, particularly secondary to any history of severe auto-immune disorder.BRAF/MEK inhibitors ha …
Decisions regarding first line therapy should include consideration of patient preference as well as the presence of symptomatic meta …
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG.
Haist M, Stege H, Rogall F, Tan Y, von Wasielewski I, Klespe KC, Meier F, Mohr P, Kähler KC, Weichenthal M, Hauschild A, Schadendorf D, Ugurel S, Lodde G, Zimmer L, Gutzmer R, Debus D, Schilling B, Kreuter A, Ulrich J, Meiss F, Herbst R, Forschner A, Leiter U, Pfoehler C, Kaatz M, Ziller F, Hassel JC, Tronnier M, Sachse M, Dippel E, Terheyden P, Berking C, Heppt MV, Kiecker F, Haferkamp S, Gebhardt C, Simon JC, Grabbe S, Loquai C. Haist M, et al. J Immunother Cancer. 2023 Sep;11(9):e007630. doi: 10.1136/jitc-2023-007630. J Immunother Cancer. 2023. PMID: 37730278 Free PMC article.
BACKGROUND: Adjuvant therapy with immune-checkpoint inhibitors (CPI) or BRAF/MEK-directed targeted therapy (TT) improves recurrence-free survival (RFS) for patients with advanced, BRAFV600-mutant (BRAFmut) resected melanoma. However, 40% of these patie …
BACKGROUND: Adjuvant therapy with immune-checkpoint inhibitors (CPI) or BRAF/MEK-directed targeted therapy (TT) improve …
Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going.
Sun C, España S, Buges C, Layos L, Hierro C, Manzano JL. Sun C, et al. Clin Colorectal Cancer. 2022 Jun;21(2):71-79. doi: 10.1016/j.clcc.2022.01.009. Epub 2022 Feb 3. Clin Colorectal Cancer. 2022. PMID: 35277355 Review.
Clinical observations indicate that colorectal cancer patients harboring the BRAF V600E mutation have a worse prognosis than BRAF wild type patients. ...This article primarily explores 3 aspects of the treatment strategies for advanced BRAF-mutated colorectal …
Clinical observations indicate that colorectal cancer patients harboring the BRAF V600E mutation have a worse prognosis than BRAF …
222 results